Mirum Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During our last fiscal quarter, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.
| Type of Trading Arrangement | ||||||
| Name and Position | Action | Adoption/Termination Date | Rule 10b5-1* | Non-Rule 10b5-1** | Total Shares of Common Stock to be Sold | Expiration |
|---|---|---|---|---|---|---|
| Christopher Peetz, Chief Executive Officer | Termination1 | June 27, 2024 | X | Up to 75,000 | December 28, 2025 | |
| Peter Radovich, President and Chief Operating Officer | Termination2 | June 27, 2024 | X | Up to 53,541 | March 26, 2025 | |
| *Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | ||||||
| **“Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. | ||||||
| 1 Represents the termination of a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) adopted on December 28, 2023. | ||||||
| 2 Represents the termination of a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) adopted on March 26, 2024. | ||||||
In addition, we inadvertently omitted from the prior reports indicated in the table below the disclosures of the Rule 10b5-1 trading arrangements set forth in the table below.
| Type of Trading Arrangement | ||||||
| Name and Position | Action | Adoption/Termination Date | Rule 10b5-1* | Non-Rule 10b5-1** | Total Shares of Common Stock to be Sold | Expiration |
|---|---|---|---|---|---|---|
| Peter Radovich, President and Chief Operating Officer | Adoption1 | March 26, 2024 | X | Up to 53,541 | March 26, 2025 | |
| Pamela Vig, Chief Scientific Officer | Adoption1 | March 20, 2024 | X | Up to 61,111 | March 21, 2025 | |
| Lara Longpre, Chief Development Officer | Adoption1 | March 26, 2024 | X | Up to 61,113 | March 26, 2026 | |
| *Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, | ||||||
| **“Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. | ||||||
| 1 In Item 5 of Part II of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, we inadvertently omitted disclosure of this Rule 10b5-1 trading arrangement. In June 2024, while they continue to serve as Chief Scientific Officer and Chief Development Officer, respectively, Dr. Vig and Ms. Longpre were determined to no longer be “officers” (as defined in Rule 16a-1(f) under the Exchange Act). | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.